PubMed · 1993 · 138 citations · 9 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyDrug DeliveryChemotherapy ResistanceCytotoxic ChemotherapyLiposomal FormulationsLiposome-based DeliveryOncology PharmacologyOvarian Cancer PharmacotherapyAnticancer ActivityAnticancer ChemotherapyAnticancer Drug ResistanceLiposome ToxicityLiposomesLow SolubilitySerious Adverse Drug ReactionsSerious Adverse Events
Taxol is a promising agent for use in ovarian cancer and other malignancies. One problem associated with taxol is its low aqueous solubility, requiring Cremophor EL (polyethoxylated castor oil) and ethanol as excipients (Diluent 12); these agents cause serious adverse effects. Liposomes containing taxol and phospholipid (in a 1:33 mole ratio, respectively) were prepared from phosphatidylglycerol and phosphatidylcholine in a 1:9 mole ratio. Antitumor effect was evaluated against Colon-26, a taxol-resistant murine tumor. Given as 1, 4, or 9 injections, free taxol given i.v. in Diluent 12 was ineffective at delaying tumor growth at doses < or = 30 mg/kg per injection (the maximum tolerated dose). In contrast, taxol-liposomes were well tolerated at doses greater than or equal to the maximum tolerated dose of free taxol and showed significant tumor growth inhibition at 10-45 mg/kg per injection.
9
Phosphorus Assay in Column Chromatography
Grant R. Bartlett · Journal of Biological Chemistry · 1959 · 12.9K citations · Full text
THE IMPACT OF NATIONAL CANCER ACT
Frankie A. Holmes, Ronald S. Walters, Richard L. Theriault et al. · JNCI Journal of the National Cancer Institute · 1991 · 803 citations
Medicine, Oncology, Pharmacology +10
Taxol: the first of the taxanes, an important new class of antitumor agents.
Eric K. Rowinsky, Nicole Onetto, Renzo Canetta et al. · PubMed · 1992 · 393 citations
Medicine, Oncology, Pharmacology +13